Byd has grown rapidly in China over the past few years, becoming the country's best-selling car brand and the world's biggest selling electric car brand. Byd opened its first electric car factory in Southeast Asia on Thursday in Thailand. Byd also took over a former Ford Motor Co. plant in Brazil and has been looking for a site for a Mexican plant. Europe's first automotive plant is under construction in Hungary. Byd's second-quarter sales jumped to a record 982,747 vehicles, up more than 40 per cent from a year earlier. Although the company's sales in Europe have been sluggish so far, it is making a big marketing push in the region to replace Volkswagen as the main automotive sponsor of the European Championship. According to a recent Fortune report, officials said that Turkish President Recep Tayyip Erdogan is expected to announce the agreement for BYD to build the plant at a signing ceremony on Monday in Manisa province, where the plant will be built. The officials spoke on condition of anonymity because they were not authorized to speak publicly. Byd representatives declined to comment. Turkish Industry and Technology Minister Mohamed Fatih Kassir said in May that he was in advanced discussions with BYD and Chery on investment in Turkey. The new plant will improve BYD's access to the European Union, as Turkey has a customs union agreement with the EU. The European Union this week announced temporary punitive tariffs on electric vehicles imported from China, with BYD imposing an additional 17.4 percent tariff on top of the existing 10 percent tariff. Other Chinese carmakers have been hit with higher tariffs. Investing in Turkey would strengthen the presence of Chinese carmakers in Europe at a time of escalating trade tensions.

Carlsberg to buy Britvic for 1,315p per share Carlsberg will also buy out Marston's from brewing joint venture Danish brewer plans to create integrated beverage business in UK Shares in Carlsberg, Britvic, Marston's all rise July 8 (Reuters) - Carlsberg (CARLb.CO), opens new tab has agreed to buy British soft drinks maker Britvic (BVIC.L), opens new tab for 3.3 billion pounds ($4.23 billion), a move the Danish brewer said would forge a UK beverage "powerhouse" and that sent both companies' shares higher. Carlsberg clinched the takeover with a sweetened bid of 1,315 pence per share - comprising cash and a special dividend of 25 pence a share - after the British company rejected 1,250 pence per share last month. The acquisition will create value for shareholders, contribute to growth and forge a combined beer and soft drink company that is unique in the UK, CEO Jacob Aarup-Andersen told investors on a conference call. "With this transaction we are creating a UK powerhouse," he said. He brushed off concerns from some analysts about integration risks, saying Carlsberg has a strong track record of running beer and soft drink businesses in several markets. Soft drinks already make up 16% of Carlsberg's volumes. COST SAVINGS As drinkers in some markets ditch beer for spirits or cut back on drinking altogether, brewers have looked to broaden their portfolio into new categories like hard seltzer, canned cocktails and cider, as well as zero-alcohol brews. Britvic sells non-alcoholic drinks in Britain, Ireland, Brazil and other international markets such as France, the Middle East and Asia. Carlsberg said the deal will deliver a number of benefits, including cost and efficiency savings worth 100 million pounds ($128 million) over five years as it takes advantage of common procurement, production and distribution networks. It will also see Carlsberg take over Britvic's bottling agreement with PepsiCo (PEP.O), opens new tab. Carlsberg already bottles PepsiCo drinks in several markets and there is scope to add more geographies in future, Aarup-Andersen said. arlsberg halted share buy backs on Monday as a result of the deal. Chief financial officer Ulrica Fearn said these would resume once Carlsberg reaches its revised target for net debt of 2.5 times EBITDA, from 3.5 times currently - a goal it expects to meet in 2027. "Whilst this represents a shift in the strategy away from organic top- and bottom-line growth and consistent returns to shareholders, we view it as a relatively low risk transaction with attractive financials," Jefferies analysts said in a note. Carlsberg also said on Monday it will buy out UK pub group Marston's (MARS.L), opens new tab from a joint venture for 206 million pounds. That will give it full ownership of the newly formed Carlsberg Britvic after the deal. ($1 = 0.7805 pounds) Get the latest news and expert analysis about the state of the global economy with Reuters Econ World. Sign up here. Reporting by Stine Jacobsen, Yadarisa Shabong and Emma Rumney Editing by Sherry Jacob-Phillips, Rashmi Aich, David Goodman and David Evans

White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.

A provocative new study reveals the complex effects of the space environment on human health, providing insight into potential damage to blood, cell structure and the immune system. The study focused on SpaceX's Inspiration4 mission, which successfully sent two men and two women into space in 2021 to orbit the Earth for three days and shed some light on the effects of space travel on the human body. The research data, derived directly from the Inspiration4 mission, shows that even a brief trip to space can significantly damage the human immune system, trigger an inflammatory response, and profoundly affect cell structure. In particular, space travel triggered unprecedented changes in cytokines that play a key role in immune response and muscle regulation but are not usually directly associated with inflammation. In particular, the study found a significant increase in muscle factors, which are physiological responses specific to skeletal muscle cells in microgravity, rather than a simple immune response. Although non-muscular tissues did not show changes in proteins associated with inflammation, specific leg muscles such as soleus and tibialis anterior muscles showed significant signs of metabolic activity, especially increased interleukin in the latter, further enhancing the activation of immune cells.

The tetraprism lens with 5x optical zoom currently exclusive to the iPhone 15 Pro Max could be headed to both the iPhone 16 Pro and iPhone 16 Pro Max, narrowing the gap between Apple's premium flagships. That's according to a new report from analyst Ming-Chi Kuo, who cites a recent earnings call with Apple lens supplier Largan. In the call, a spokesperson from Largan said "some flagship specifications will be extended to other models" in the second half of 2024, presumably in reference to the upcoming iPhone Pro models. "Apple is Largan’s largest customer, and Largan is also Apple’s largest lens supplier," Kuo said. "Therefore, the quote likely refers to the fact that the new iPhone 16 Pro and Pro Max will have a tetraprism camera in 2H24 (while only the iPhone 15 Pro Max had this camera in 2H23).” The report goes on to say that the tetraprism camera for the iPhone 16 Pro series won't be all that different from the one in the iPhone 15 Pro Max. While the lack of an upgrade is disappointing, it's not necessarily a bad thing as these kinds of lenses are already top-of-the-line. They represent a major increase over prior models’ zoom capabilities, and they're capable of offering more depth while still fitting into super-slim smartphones. That being said, Apple does appear to be revamping the main camera and ultra-wide camera on the iPhone 16 Pro Max. Evidence continues to mount that both iPhone 16 Pro models will share the same 5x optical zoom camera. Earlier this week, DigitTimes in Asia (via 9to5Mac) reported that Apple is set to ramp up orders for tetraprism lenses as it expands their use in its upcoming iPhone series. Industry sources told the outlet that Largan and Genius Electronic Optical were tapped as the primary suppliers. Apple would be wise to streamline its Pro-level iPhones with the same camera setup; then all customers have to consider with their choice of a new iPhone is the size and price. Of course, this should all be taken with a grain of sand for now until we hear more from Apple. It's still a while yet before Apple's usual September time window for iPhone launches. In the meantime, be sure to check out all the rumors so far in our iPhone 16, iPhone 16 Pro and iPhone 16 Pro Max hubs.